BridgeBio Pharma Inc (BBIO) concluded trading on Thursday at a closing price of $25.63, with 2.36 million shares of worth about $60.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.95% during that period and on October 03, 2024 the price saw a gain of about 2.19%. Currently the company’s common shares owned by public are about 175.08M shares, out of which, 146.91M shares are available for trading.
Stock saw a price change of 4.70% in past 5 days and over the past one month there was a price change of -16.43%. Year-to-date (YTD), BBIO shares are showing a performance of -36.51% which increased to 0.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.62 but also hit the highest price of $44.32 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 1.85 million. The stock is currently trading -4.33% below its 20-day simple moving average (SMA20), while that difference is down -1.83% for SMA50 and it goes to -13.58% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 175.08M outstanding shares and institutions hold larger chunk of about 75.07% of that.
The stock has a current market capitalization of $4.82B and its 3Y-monthly beta is at 1.08. It has posted earnings per share of -$2.64 in the same period. It has Quick Ratio of 4.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 5.13% while standing at 4.91% over the month.
Stock’s fiscal year EPS is expected to rise by 37.84% while it is estimated to decrease by -26.27% in next year. EPS is likely to grow at an annualized rate of 26.80% for next 5-years, compared to annual growth of -13.29% made by the stock over the past 5-years.
Coverage by Piper Sandler stated BridgeBio Pharma Inc (BBIO) stock as an Overweight in their note to investors on September 04, 2024, suggesting a price target of $46 for the stock. On March 21, 2024, Raymond James Resumed their recommendations, while on January 31, 2024, BMO Capital Markets Initiated their ratings for the stock with a price target of $37. Stock get an Overweight rating from Wells Fargo on December 08, 2023.
